SECURITIES PURCHASE PLANSecurities Purchase Plan • March 18th, 2020 • Sumitomo Chemical Co., Ltd. • Pharmaceutical preparations
This agreement with respect to the securities purchase plan, as supplemented by Appendix A attached hereto (the “Purchase Plan”), is entered into on March 13, 2020, by and between Citigroup Global Markets Inc. (“CGMI”) and Sumitovant Biopharma Ltd (the “Company”), with respect to the purchase of common shares, par value $0.000017727 (the “Securities”), issued by Myovant Sciences Ltd. (“Myovant”) and listed on the New York Stock Exchange (the “Principal Market”). The Purchase Plan is intended to comply with the principles of Rule 10b5-1 (“Rule 10b5-1”) and Rule 10b-18 (“Rule 10b-18”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). CGMI will act as exclusive agent of the Company under this Purchase Plan.
